Matthew Breyer

Matthew Breyer

Company: Janssen

Job title: Distinguished Scientist CVM


Matt received his M.D from Harvard in 1979.  Following residency and nephrology training he served as Professor of Medicine in the division of Nephrology from 1985-2007 at Vanderbilt University Medical School, where his work focused on prostanoids and the use of transgenic mouse models to study diabetic kidney disease and hypertension.  Dr. Breyer held numerous NIH and VA grants and from 2001-2006 headed the nephropathy sub-group of the NIH Animal Models of Diabetic Complications Consortium (AMDCC).  As a result of his interest in developing treatments for diabetic nephropathy he moved to Eli Lilly in 2007 to oversee a program to develop bio-therapeutics for diabetic kidney disease.  In 2009 he was appointed to the position of Chief Scientific Officer Lead Generation Biotechnology Discovery Research at Eli Lilly where he oversaw preclinical target

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.